SCHEMBL3363350

SCHEMBL3363350

N=c1ccc2nc3ccc(N)cc3oc-2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.47
NPC1 O15118 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPT P10636 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HPGD P15428 2/20 0.47
GLA P06280 1/20 0.47
GAA P10253 1/20 0.47
APP P05067 11/20 0.46
CYP1A2 P05177 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
ALPL P05186 1/20 0.39
POLB P06746 1/20 0.39
ALPI P09923 1/20 0.39
ALPG P10696 1/20 0.39
RECQL P46063 1/20 0.39
PIK3CG P48736 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1635563 0.81 APP (0.68) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL12203258 0.81 APP (0.68) APPCYP1A2
SCHEMBL18216975 0.81 HSD17B10 (0.50) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL13926528 0.78 RAB9A (0.44) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL21924480 0.78 APP (0.43) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL17716522 0.76 RAB9A (0.42) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL14338730 0.75 MEN1 (0.51) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL13810526 0.75 APP (0.43) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL308355 0.71 CA2 (0.42) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL615340 0.71 SMN1; SMN2 (0.58) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001562-B2 Near-infrared fluorescent nerve contrast agents and methods of use thereof BETH ISRAEL DEACONESS MEDICAL CENTER (US) 2021-05-11 US disclosed
US-20160347727-A1 NEAR-INFRARED FLUORESCENT NERVE CONTRAST AGENTS AND METHODS OF USE THEREOF BETH ISRAEL DEACONESS MEDICAL CT INC (US) 2016-12-01 US disclosed
WO-2015066296-A9 NEAR-INFRARED FLUORESCENT NERVE CONTRAST AGENTS AND METHODS OF USE THEREOF BETH ISRAEL DEACONESS MEDICAL CENTER (US) 2015-07-09 WO disclosed
WO-2015066296-A1 NEAR-INFRARED FLUORESCENT NERVE CONTRAST AGENTS AND METHODS OF USE THEREOF BETH ISRAEL DEACONESS MEDICAL CENTER (US) 2015-05-07 WO disclosed
US-20130053252-A1 NUCLEIC ACID AMPLIFICATION AND SEQUENCING BY SYNTHESIS WITH FLUOROGENIC NUCLEOTIDES PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) 2013-02-28 US disclosed
US-8034928-B2 Fluorescence assays with improved sensitivity WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2011-10-11 US disclosed
US-8034928-B2 Fluorescence assays with improved sensitivity WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2011-10-11 US disclosed
WO-2010138960-A2 METHODS AND SYSTEMS FOR SINGLE-MOLECULE RNA EXPRESSION PROFILING PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2010-12-02 WO disclosed
US-20100227327-A1 METHODS AND COMPOSITIONS FOR CONTINUOUS SINGLE-MOLECULE NUCLEIC ACID SEQUENCING BY SYNTHESIS WITH FLUOROGENIC NUCLEOTIDES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-09-09 US disclosed
US-20100036110-A1 METHODS AND COMPOSITIONS FOR CONTINUOUS SINGLE-MOLECULE NUCLEIC ACID SEQUENCING BY SYNTHESIS WITH FLUOROGENIC NUCLEOTIDES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-02-11 US disclosed
WO-2010017487-A1 METHODS AND COMPOSITIONS FOR CONTINUOUS SINGLE-MOLECULE NUCLEIC ACID SEQUENCING BY SYNTHESIS WITH FLUOROGENIC NUCLEOTIDES PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2010-02-11 WO disclosed
US-20090299061-A1 FLUORESCENCE ASSAYS WITH IMPROVED SENSITIVITY PENN STATE RESEARCH FOUNDATION 2009-12-03 US disclosed
US-20090299061-A1 FLUORESCENCE ASSAYS WITH IMPROVED SENSITIVITY PENN STATE RESEARCH FOUNDATION 2009-12-03 US disclosed
US-7534902-B2 Fluorescence assays with improved sensitivity WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2009-05-19 US disclosed
US-7534902-B2 Fluorescence assays with improved sensitivity WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2009-05-19 US disclosed
US-20080213535-A1 Oriented Zeolite Material and Method for Producing the Same UNIVERSITAT BERN (CH) 2008-09-04 US disclosed
US-20080213535-A1 Oriented Zeolite Material and Method for Producing the Same UNIVERSITAT BERN (CH) 2008-09-04 US disclosed
WO-2007012216-A2 ORIENTED ZEOLITE MATERIAL AND METHOD FOR PRODUCING THE SAME Universität Bern (CH) 2007-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227327-A1 METHODS AND COMPOSITIONS FOR CONTINUOUS SINGLE-MOLECULE NUCLEIC ACID SEQUENCING BY SYNTHESIS WITH FLUOROGENIC NUCLEOTIDES RNGTT, NOP2, RNMT RAB9A 2493/4885NPC1 438/4885SMN1; SMN2 1803/4885
US-20160347727-A1 NEAR-INFRARED FLUORESCENT NERVE CONTRAST AGENTS AND METHODS OF USE THEREOF INA, NTRK1, NGF RAB9A 1838/4885NPC1 713/4885SMN1; SMN2 49/4885
US-20090299061-A1 FLUORESCENCE ASSAYS WITH IMPROVED SENSITIVITY UACA, HNRNPUL1, FUS RAB9A 3862/4885NPC1 2630/4885SMN1; SMN2 4340/4885
US-20130053252-A1 NUCLEIC ACID AMPLIFICATION AND SEQUENCING BY SYNTHESIS WITH FLUOROGENIC NUCLEOTIDES RNGTT, POLI, NT5E RAB9A 2958/4885NPC1 1742/4885SMN1; SMN2 3671/4885
US-11001562-B2 Near-infrared fluorescent nerve contrast agents and methods of use thereof INA, NTRK1, NGF RAB9A 1838/4885NPC1 713/4885SMN1; SMN2 49/4885
US-20100036110-A1 METHODS AND COMPOSITIONS FOR CONTINUOUS SINGLE-MOLECULE NUCLEIC ACID SEQUENCING BY SYNTHESIS WITH FLUOROGENIC NUCLEOTIDES RNGTT, DNMT3A, NOP2 RAB9A 2733/4885NPC1 1028/4885SMN1; SMN2 1914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.